Reason: MRNA/VRTX are the confirmed hot pocket — both RSI >81 and parabolic (MRNA +114.7% vs VWAP) — but that means trim, not chase; AMGN/TMO are the only clean, non-frothy accumulate setups left in the sector.

Tape-read: Biotech got more extended over the last ten sessions, not less — XBI/IBB/IBBQ are all RSI 77-79, and MRNA/VRTX are now the two most extreme names in the whole scan (RSI 81.9 and 81.6). This confirms the desk-wide "biotech (MRNA/VRTX parabolic)" hot-pocket call directly — but a hot pocket that's already 100%+ above VWAP is a protect-the-position signal, not a fresh candidate. The gene-editing cohort (EDIT/NTLA/CRSP/ILMN/RXRX) broke out together in the same window — a real cohort move, not noise, but also fully priced for now. The only sector names still under +13% vs VWAP and not near a 52-week high are the large-cap basers: AMGN, GILD, TMO, BMRN. Source: 2026-07-07-biotech-scan + summaries/biotech.json.

• MRNA — PASS (trim/protect): RSI 81.9, strong-up, +71.9% 30D, +114.7% above VWAP — the most parabolic name in the dataset. Confirmed hot pocket, but not a new position; trail stops if owned.
• VRTX — PASS (trim/protect): RSI 81.6, near-ATH (-0.08% from 52wk high), +19.6% 30D — crossed into the same extreme tier as MRNA this scan. Hold only.
• AMGN — PROMOTE: RSI 63.0, strong-up, golden cross, only +12.8% vs VWAP, not near its high — the cleanest large-cap accumulate two scans running.
• TMO — WATCH/PROMOTE: RSI 63.5, weak-up (still death-crossed on the shorter trend), +10.3% 30D — the strongest weekly print of the basing cohort; add on a pullback toward SMA20 (~$487).

Lead pick: AMGN — RSI 63, golden cross, un-extended vs VWAP, two straight scans of clean basing. MRNA and VRTX are the names to watch for a reversal, not to buy — both need a real catalyst to hold current levels, not just momentum.